ViQi, Inc. awarded a National Science Foundation grant SBIR Phase II: Machine learning for Rapid Automated Viral Infectivity Assays
SANTA BARBARA, Calif., April 21, 2022 /PRNewswire-PRWeb/ -- Development of viral vaccines and antiviral drugs requires viral infectivity assays, however, the incubation periods of plaque and TCID50 assays can be as long as 14 days, and the alternatives like focus forming assay (FFA) require antibodies and extensive sample preparation or developing GFP-labeled viruses which is not always possible or desirable. This automated viral infectivity assay is based on brightfield microscopy, not requiring any stains or labels. A one time calibration of the machine learning model on a specific combination of virus, cell line, and imager is required to detect phenotypic changes associated with early stages of active virus infection in cells before being humanly visible. Detection can be done within hours (same-day) for fast-acting viruses or in as long as two days for viruses that take up to two weeks to develop infections detectable by conventional means. Not only will this assay significantly reduce the turn-around time and processing steps required, it can also be completely automated with conventional equipment used for high-content screening.
- ViQi Inc, a California image analysis company specializing in enabling the use of artificial intelligence in the scientific discovery process, announced today the confirmation of Phase II National Science Foundation (NSF) grant to further optimize their cloud analysis solution applying machine learning to automate viral infectivity assays, significantly reducing the time required for these assays.
- This automated viral infectivity assay is based on brightfield microscopy, not requiring any stains or labels.
- Not only will this assay significantly reduce the turn-around time and processing steps required, it can also be completely automated with conventional equipment used for high-content screening.
- America's Seed Fund powered by the National Science Foundation (NSF) awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact.